EZH2 and hepatocellular carcinoma: Collectively, these findings demonstrate that <i>EZH2</i> and <i>LSD1</i> cooperatively sustain <i>GLI1</i>-dependent SHH signaling in HCC, and that dual epigenetic inhibition represents a mechanistically defined therapeutic strategy.